Adaptive Biotechnologies (ADPT) opened Q1 2026 with revenue of US$70.9 million and a basic EPS loss of US$0.13, alongside a net loss of US$20.0 million. Over recent quarters the company has seen revenue move from US$47.5 million in Q4 2024 to US$52.4 million in Q1 2025, US$58.9 million in Q2 2025, US$94.0 million in Q3 2025 and US$71.7 million in Q4 2025. Quarterly EPS ranged from a loss of US$0.23 in Q4 2024 to a profit of US$0.06 in Q3 2025 and back to a loss of US$0.09 in Q4 2025, putting the latest quarter’s loss in focus as investors weigh how revenue scale is feeding through to margins.
See our full analysis for Adaptive Biotechnologies.With the headline numbers on the table, the next step is to see how this earnings print lines up with the prevailing bull and bear narratives that have built around Adaptive Biotechnologies over the past year.
See what the community is saying about Adaptive Biotechnologies
Trailing losses narrow but still meaningful
- Over the last 12 months, Adaptive Biotechnologies booked US$295.4 million in revenue and a net loss of US$49.7 million, with trailing EPS at a loss of US$0.32 compared with a loss of US$0.96 a year earlier on US$189.5 million in revenue and a US$141.8 million loss.
- Consensus narrative points to improving profitability as a key theme, and the data partly backs that up, yet also highlights the gap that still needs closing:
- Losses over the past five years have reportedly shrunk at about 13.2% per year, which fits the idea of gradual progress, but the latest trailing net loss of US$49.7 million shows the business is still far from the US Life Sciences industry margin of 15.4% referenced in the consensus assumptions.
- Analysts are assuming revenue growth of around 14.5% a year for the next three years, broadly in line with the 14.6% forecast in the risk and reward data. However, the company is still expected to remain unprofitable over that period in those same datasets, which puts a clear check on the most optimistic profit expectations.
Revenue growth meets rich valuation
- The stock trades at a P/S of 7.8x compared with 3.4x for the broader US Life Sciences industry and 8.5x for its peer group, while a DCF fair value of US$21.51 sits above the current share price of US$14.43.
- Supporters of the bullish view often lean on the growth and modelled upside, and the numbers give both support and pushback:
- Forecast revenue growth of roughly 14.6% per year and a DCF fair value that is about 49% above the current price heavily support the idea that the market may be undervaluing future cash flows, at least relative to that model.
- At the same time, paying a P/S of 7.8x for a company that is not expected to be profitable over the next three years, when the broader industry averages 3.4x, challenges the bullish assumption that earnings power will catch up quickly enough to justify a higher multiple.
Quarterly swings keep risk in play
- Over the last six reported quarters, revenue moved from US$47.5 million in Q4 2024 to US$93.97 million in Q3 2025 and US$70.87 million in Q1 2026, while quarterly net income ranged from a US$33.7 million loss in Q4 2024 to a US$9.5 million profit in Q3 2025 and back to a US$20.0 million loss in Q1 2026.
- Consensus narrative highlights growing clinical adoption and better reimbursement as drivers of steadier, higher quality revenue, but the reported numbers still flag some points cautious investors focus on:
- The shift from a US$9.5 million profit in Q3 2025 to a US$13.6 million loss in Q4 2025 and a US$20.0 million loss in Q1 2026 shows that profitability is not yet consistent, which aligns with the risk section that expects the business to remain loss making over the next three years.
- Recent data also records significant insider selling over the past three months, which critics view alongside the ongoing losses as a reminder that, even with growing revenue and a positive DCF gap, execution risk around reaching stable profitability is still front and center.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Adaptive Biotechnologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
Unsure whether the latest numbers justify the current price? Take a closer look at the data now and weigh up the 4 key rewards and 2 important warning signs.
See What Else Is Out There
Adaptive Biotechnologies is still recording meaningful losses and trading on a richer P/S multiple than the broader US Life Sciences industry, so valuation risk remains front and center.
If that combination of ongoing losses and a premium price tag makes you cautious, compare it with companies that look cheaper on the numbers using the 44 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com